Skip to main content
Toggle navigation
Search
Home
Silver
Home
Silver
Silver
Type here to filter the list
(36) Descriptive Analysis of ATTR-CM Patients Initiating Tafamidis Among Medicare Advantage Enrollees.
(41) Olezarsen and plozasiran in the treatment of familial chylomicronemia syndrome (FCS): Results from a matching-adjusted indirect comparison (MAIC)
(47) Payer policies and access restrictions for CRISPR-based gene therapy in sickle cell disease and beta-thalassemia: A systematic review of U.S. coverage frameworks
(117) Accelerating quality gap closure with artificial intelligence: Clinical natural language processing and large language model-driven extraction of HEDIS measures from structured and unstructured medical records
(207) Examining the Impact of Specialty Drug Rebates on Health Plan Coverage Decisions
(246) Quantifying the productivity burden of lupus nephritis and the potential value of obinutuzumab treatment
(256) Impact of Medications for Opioid Use Disorder on Infectious Disease Management
(302) Managed care approaches to bispecific antibodies (BsAbs) in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): AMCP Market Insights Program
(308) A survey of healthcare decision maker (HCDM) formulary management perspectives in crowded oncologic markets: a focus on advanced non-small cell lung cancer (aNSCLC) and relapsed/refractory multiple myeloma (RRMM)
(314) Recent Real-World Treatment Patterns of Advanced Melanoma in the United States
(330) Budget impact of darolutamide + ADT for mCSPC from a United States payer perspective
(367) Healthcare costs associated with timely diagnosis of mild cognitive impairment and Alzheimer's Disease
